While Brexit provided an expected boost to core earnings for GlaxoSmithKline, it also led to a big write-down—the latest in a series of surprises stemming from Britain’s vote to leave the EU.
WSJ.com: US Business, Wall Street Journal: Business
Wed, 07/27/2016 - 4:16pm
While Brexit provided an expected boost to core earnings for GlaxoSmithKline, it also led to a big write-down—the latest in a series of surprises stemming from Britain’s vote to leave the EU.